Inclinix, Inc., a contract research organization (CRO) specializing in clinical trial enrollment solutions, announces the expansion of its in-field Regional Recruitment Manager (RRM) team, including international and multi-lingual professionals.
WILMINGTON, N.C., Oct. 15 /PRNewswire/-Inclinix, Inc., a contract research organization (CRO) specializing in clinical trial enrollment solutions, announces the expansion of its in-field Regional Recruitment Manager (RRM) team, including international and multi-lingual professionals. In response to the emergent demand for enrollment experts in the field to assist with difficult to enroll studies, Inclinix has increased the team by 200%.
Regional Recruitment Managers are enrollment experts, clinically experienced across multiple therapeutic areas and trained to develop and execute site-specific patient recruitment strategies. These professionals identify patient recruitment opportunities and challenges both within the site and its adjacent community. In addition to providing hands-on resources to site staff to identify potential study participants, RRMs serve an important role in the continuing education and promotion of studies within healthcare networks supporting and surrounding the site. This unique outreach drives study participation while educating healthcare providers and other patient advocates.
Tobin Geatz, President and CEO of Inclinix says, "the industry is demanding new and innovative strategies to solve the day-to-day challenges of patient recruitment." Geatz further states, "our sponsors know our reputation as experts in patient recruitment, and have easily adopted our Regional Recruitment Managers as a solution to make their sites more productive."
Regional Recruitment Managers are critical to successful enrollment, particularly in trials requiring special populations, low incidences of disease, or in difficult-to-enroll trials where traditional recruitment tactics may be less effective. In a recent study of a special population, RRMs increased enrollment by 60% over sites not supported with RRMs. On average, sites supported with RRMs exceed monthly screening goals and contribute to successful enrollment milestones.
Inclinix clients have benefited from successful programs in therapeutic areas including congestive heart failure, pediatric hypertension,
post-operative pain and pre-term labor. With the expanded Regional Recruitment Manager team, Inclinix will steadily pursue enrollment challenges that cannot be met by traditional patient recruitment methods.
About Inclinix
Inclinix, Inc. is a CRO specializing in customized Phase I-IV clinical trial enrollment solutions for global pharmaceutical, biotechnology, and medical device organizations. Clients benefit from ten years of experience in multiple therapeutic areas, as well as leading edge technologies that meet the challenge of clinical development from feasibility through compliance. In addition, Inclinix provides strategic medical marketing communications and adherence services to the healthcare industry.
For more information, visit www.inclinix.com.
SOURCE Inclinix, Inc.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.